ALTUVIIIO
These highlights do not include all the information needed to use ALTUVIIIO safely and effectively. See full prescribing information for ALTUVIIIO. ALTUVIIIO™ [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl], lyophilized powder for solution, for intravenous use Initial U.S. Approval: 2023
01411972-df40-4ccf-88f0-d3220e5abda9
HUMAN PRESCRIPTION DRUG LABEL
Mar 31, 2023
Bioverativ Therapeutics Inc.
DUNS: 070517011
Products 6
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl
Product Details
FDA regulatory identification and product classification information